{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:11:50Z","timestamp":1770919910844,"version":"3.50.1"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Autoantibodies hold promise for diagnosing lung cancer. However, their effectiveness in early-stage detection needs improvement. In this study, we investigated novel IgG and IgM autoantibodies for detecting early-stage lung adenocarcinoma (Early-LUAD) by employing a\u00a0multi-step approach, including Human Proteome Microarray (HuProtTM) discovery, focused microarray verification, and ELISA validation, on 1246 individuals consisting of 634 patients with Early-LUAD (stage 0\u2013I), 280 patients with benign lung disease (BLD), and 332 normal healthy controls (NHCs). HuProtTM selected 417 IgG\/IgM candidates, and focused microarray further verified 55 significantly elevated IgG\/IgM autoantibodies targeting 32 tumor-associated antigens in Early-LUAD compared to BLD\/NHC\/BLD+NHC. A novel panel of 10 autoantibodies (ELAVL4-IgM, GDA-IgM, GIMAP4-IgM, GIMAP4-IgG, MGMT-IgM, UCHL1-IgM, DCTPP1-IgM, KCMF1-IgM, UCHL1-IgG, and WWP2-IgM) demonstrated a sensitivity of 70.5% and a specificity of 77.0% or 80.0% for\u00a0distinguishing Early-LUAD from BLD or NHC in ELISA validation. Positive predictive values for distinguishing Early-LUAD from BLD with nodules \u2264 8 mm, 9\u201320 mm, and &amp;gt; 20 mm significantly increased from 47.27%, 52.00%, and 62.90% [low-dose computed tomography (LDCT) alone] to 79.17%, 71.13%, and 87.88% (10-autoantibody panel combined with LDCT), respectively. The combined risk score (CRS), based on the 10-autoantibody panel, sex, and imaging maximum diameter, effectively stratified the risk for Early-LUAD. Individuals with 10 \u2264 CRS \u2264 25 and CRS &amp;gt; 25 indicated a higher risk of Early-LUAD compared to the reference (CRS &amp;lt; 10), with adjusted odds ratios of 5.28 [95% confidence interval (CI): 3.18\u20138.76] and 9.05 (95% CI: 5.40\u201315.15), respectively. This novel panel of IgG and IgM autoantibodies offers a complementary approach to LDCT in distinguishing Early-LUAD from benign nodules.<\/jats:p>","DOI":"10.1093\/gpbjnl\/qzae085","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T22:21:48Z","timestamp":1733955708000},"source":"Crossref","is-referenced-by-count":2,"title":["A Novel IgG\u2013IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0702-8471","authenticated-orcid":false,"given":"Rongrong","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-3558","authenticated-orcid":false,"given":"Xiying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3683-8734","authenticated-orcid":false,"given":"Ruyun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0652-6212","authenticated-orcid":false,"given":"Mengwei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8336-1415","authenticated-orcid":false,"given":"Juan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4848-3709","authenticated-orcid":false,"given":"Liyuan","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-1192","authenticated-orcid":false,"given":"Nin","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-0007","authenticated-orcid":false,"given":"Guangyu","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-0289","authenticated-orcid":false,"given":"Haohua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-0537","authenticated-orcid":false,"given":"Shasha","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-0216","authenticated-orcid":false,"given":"Zhishang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5192-3329","authenticated-orcid":false,"given":"Le","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9835-395X","authenticated-orcid":false,"given":"Jiarui","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1894-0355","authenticated-orcid":false,"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases , Beijing 100021,","place":["China"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-0167","authenticated-orcid":false,"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research & Evaluation of Drug, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 100730,","place":["China"]}]}],"member":"286","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"2025042605015008200_qzae085-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025042605015008200_qzae085-B2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1038\/s41467-020-16295-5","article-title":"Genetic and epigenetic intratumor heterogeneity impacts prognosis of lung adenocarcinoma","volume":"11","author":"Hua","year":"2020","journal-title":"Nat Commun"},{"key":"2025042605015008200_qzae085-B3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/annonc\/mds476","article-title":"From randomized trials to the clinic: is it time to implement individual lung cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d\u2019oncologie de langue francaise (GOLF)","volume":"24","author":"Couraud","year":"2013","journal-title":"Ann Oncol"},{"key":"2025042605015008200_qzae085-B4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"2025042605015008200_qzae085-B5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/RTI.0000000000000367","article-title":"An update on the european lung cancer screening trials and comparison of lung cancer screening recommendations in Europe","volume":"34","author":"Han","year":"2019","journal-title":"J Thorac Imaging"},{"key":"2025042605015008200_qzae085-B6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic \u2014 implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2025042605015008200_qzae085-B7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4251\/wjgo.v7.i12.492","article-title":"Targeting cancer testis antigens for biomarkers and immunotherapy in colorectal cancer: current status and challenges","volume":"7","author":"Suri","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"2025042605015008200_qzae085-B8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.trecan.2017.02.003","article-title":"Autoantibodies: opportunities for early cancer detection","volume":"3","author":"Macdonald","year":"2017","journal-title":"Trends Cancer"},{"key":"2025042605015008200_qzae085-B9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/annonc\/mdq361","article-title":"Clinical validation of an autoantibody test for lung cancer","volume":"22","author":"Boyle","year":"2011","journal-title":"Ann Oncol"},{"key":"2025042605015008200_qzae085-B10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2013.10.008","article-title":"Audit of the autoantibody test, EarlyCDT-Lung, in 1600 patients: an evaluation of its performance in routine clinical practice","volume":"83","author":"Jett","year":"2014","journal-title":"Lung Cancer"},{"key":"2025042605015008200_qzae085-B11","first-page":"2000670","article-title":"Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging","volume":"57","author":"Sullivan","year":"2021","journal-title":"Eur Respir J"},{"key":"2025042605015008200_qzae085-B12","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jtho.2016.08.143","article-title":"Autoantibody signature enhances the positive predictive power of computed tomography and nodule-based risk models for detection of lung cancer","volume":"12","author":"Massion","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2025042605015008200_qzae085-B13","doi-asserted-by":"crossref","first-page":"e1384108","DOI":"10.1080\/2162402X.2017.1384108","article-title":"Early detection of lung cancer by using an autoantibody panel in Chinese population","volume":"7","author":"Ren","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025042605015008200_qzae085-B14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"2025042605015008200_qzae085-B15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-019-0207-1","article-title":"Autoantibodies as diagnostic biomarkers for lung cancer: a systematic review","volume":"5","author":"Yang","year":"2019","journal-title":"Cell Death Discov"},{"key":"2025042605015008200_qzae085-B16","doi-asserted-by":"crossref","first-page":"e1310359","DOI":"10.1080\/2162402X.2017.1310359","article-title":"Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer","volume":"6","author":"Dai","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025042605015008200_qzae085-B17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1476-4598-13-78","article-title":"A novel autoantibody test for the detection of pre-neoplastic lung lesions","volume":"13","author":"Lowe","year":"2014","journal-title":"Mol Cancer"},{"key":"2025042605015008200_qzae085-B18","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1158\/1078-0432.CCR-10-0193","article-title":"Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer","volume":"16","author":"Wu","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025042605015008200_qzae085-B19","doi-asserted-by":"crossref","first-page":"102674","DOI":"10.1016\/j.ebiom.2020.102674","article-title":"Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma","volume":"53","author":"Li","year":"2020","journal-title":"EBioMedicine"},{"key":"2025042605015008200_qzae085-B20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cell.2020.09.034","article-title":"Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)","volume":"183","author":"Gruber","year":"2020","journal-title":"Cell"},{"key":"2025042605015008200_qzae085-B21","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1007\/s00432-022-04360-z","article-title":"Plasma autoantibodies IgG and IgM to PD1\/PDL1 as potential biomarkers and risk factors of lung cancer","volume":"149","author":"Li","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025042605015008200_qzae085-B22","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.7150\/ijms.47463","article-title":"The combination of IgA and IgG autoantibodies against transcriptional intermediary factor-1\u03b3 contributes to the early diagnosis of lung cancer","volume":"17","author":"Yu","year":"2020","journal-title":"Int J Med Sci"},{"key":"2025042605015008200_qzae085-B23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1074\/mcp.RA119.001905","article-title":"Integration of IgA and IgG autoantigens improves performance of biomarker panels for early diagnosis of lung cancer","volume":"19","author":"Pan","year":"2020","journal-title":"Mol Cell Proteomics"},{"key":"2025042605015008200_qzae085-B24","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201753","article-title":"Four keys to unlock IgG","volume":"218","author":"Nimmerjahn","year":"2021","journal-title":"J Exp Med"},{"key":"2025042605015008200_qzae085-B25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41577-019-0261-1","article-title":"Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA","volume":"20","author":"Chen","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025042605015008200_qzae085-B26","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s13277-013-1271-4","article-title":"Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumour Biol"},{"key":"2025042605015008200_qzae085-B27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12094-012-0980-2","article-title":"A study of circulating anti-CD25 antibodies in non-small cell lung cancer","volume":"15","author":"Ye","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"2025042605015008200_qzae085-B28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00432-012-1260-9","article-title":"Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?","volume":"138","author":"Liu","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025042605015008200_qzae085-B29","first-page":"7995","article-title":"Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans","volume":"63","author":"Brandlein","year":"2003","journal-title":"Cancer Res"},{"key":"2025042605015008200_qzae085-B30","doi-asserted-by":"crossref","first-page":"728853","DOI":"10.3389\/fimmu.2021.728853","article-title":"A diagnostic model with IgM autoantibodies and carcinoembryonic antigen for early detection of lung adenocarcinoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2025042605015008200_qzae085-B31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1940-6207.CAPR-10-0328","article-title":"EarlyCDT-lung: an immunobiomarker test as an aid to early detection of lung cancer","volume":"4","author":"Lam","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"2025042605015008200_qzae085-B32","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/cas.14371","article-title":"The diagnostic value of a seven-autoantibody panel and a nomogram with a scoring table for predicting the risk of non-small-cell lung cancer","volume":"111","author":"Wang","year":"2020","journal-title":"Cancer Sci"},{"key":"2025042605015008200_qzae085-B33","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1007\/s00432-020-03309-4","article-title":"Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules","volume":"146","author":"Huo","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025042605015008200_qzae085-B34","doi-asserted-by":"crossref","first-page":"e1625689","DOI":"10.1080\/2162402X.2019.1625689","article-title":"Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection","volume":"8","author":"Zang","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025042605015008200_qzae085-B35","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1074\/mcp.RA117.000212","article-title":"Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach","volume":"16","author":"Pan","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"2025042605015008200_qzae085-B36","doi-asserted-by":"crossref","first-page":"658922","DOI":"10.3389\/fimmu.2021.658922","article-title":"Discovering panel of autoantibodies for early detection of lung cancer based on focused protein array","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"2025042605015008200_qzae085-B37","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.7150\/thno.42096","article-title":"The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase","volume":"10","author":"Ding","year":"2020","journal-title":"Theranostics"},{"key":"2025042605015008200_qzae085-B38","first-page":"55","article-title":"Identification of ELAVL4 as a modulator of radiation sensitivity in A549 non-small cell lung cancer cells","volume":"26","author":"Choi","year":"2011","journal-title":"Oncol Rep"},{"key":"2025042605015008200_qzae085-B39","first-page":"2042","article-title":"Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+\u00a0T cells","volume":"119","author":"Roberts","year":"2009","journal-title":"J Clin Invest"},{"key":"2025042605015008200_qzae085-B40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.taap.2017.07.003","article-title":"Single-cell RNA sequencing reveals an altered gene expression pattern as a result of CRISPR\/cas9-mediated deletion of gene 33\/Mig6 and chronic exposure to hexavalent chromium in human lung epithelial cells","volume":"330","author":"Park","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"2025042605015008200_qzae085-B41","first-page":"4515","article-title":"Application of serum ELAVL4 (HuD) antigen assay for small cell lung cancer diagnosis","volume":"37","author":"Wang","year":"2017","journal-title":"Anticancer Res"},{"key":"2025042605015008200_qzae085-B42","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.jmedchem.6b01786","article-title":"Identification of triazolothiadiazoles as potent inhibitors of the dCTP pyrophosphatase 1","volume":"60","author":"Llona-Minguez","year":"2017","journal-title":"J Med Chem"},{"key":"2025042605015008200_qzae085-B43","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1021\/acs.jmedchem.7b00182","article-title":"Piperazin-1-ylpyridazine derivatives are a novel class of human dCTP pyrophosphatase 1 inhibitors","volume":"60","author":"Llona-Minguez","year":"2017","journal-title":"J Med Chem"},{"key":"2025042605015008200_qzae085-B44","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.4081\/ejh.2013.e29","article-title":"dCTP pyrophosphohydrase exhibits nucleic accumulation in multiple carcinomas","volume":"57","author":"Zhang","year":"2013","journal-title":"Eur J Histochem"},{"key":"2025042605015008200_qzae085-B45","doi-asserted-by":"crossref","first-page":"679739","DOI":"10.3389\/fimmu.2021.679739","article-title":"The GIMAP family proteins: an incomplete puzzle","volume":"12","author":"Limoges","year":"2021","journal-title":"Front Immunol"},{"key":"2025042605015008200_qzae085-B46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.lungcan.2008.03.021","article-title":"Dysregulation of GIMAP genes in non-small cell lung cancer","volume":"62","author":"Shiao","year":"2008","journal-title":"Lung Cancer"},{"key":"2025042605015008200_qzae085-B47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2005-11-4616","article-title":"Gimap4 accelerates T-cell death","volume":"108","author":"Schnell","year":"2006","journal-title":"Blood"},{"key":"2025042605015008200_qzae085-B48","doi-asserted-by":"crossref","first-page":"7440189","DOI":"10.1155\/2022\/7440189","article-title":"Prognostic value of GIMAP4 and its role in promoting immune cell infiltration into tumor microenvironment of lung adenocarcinoma","volume":"2022","author":"Chen","year":"2022","journal-title":"Biomed Res Int"},{"key":"2025042605015008200_qzae085-B49","article-title":"The detection and analysis of differential regulatory communities in lung cancer. Genomics 2020;112:2535\u201340.","author":"Lan"},{"key":"2025042605015008200_qzae085-B50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbrc.2016.07.084","article-title":"Elevated expression of WWP2 in human lung adenocarcinoma and its effect on migration and invasion","volume":"479","author":"Yang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"2025042605015008200_qzae085-B51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/carcin\/bgz144","article-title":"ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-p27 axis","volume":"41","author":"Wang","year":"2020","journal-title":"Carcinogenesis"},{"key":"2025042605015008200_qzae085-B52","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-15-0243","article-title":"Implication of a chromosome 15q15.2 locus in regulating UBR1 and predisposing smokers to MGMT methylation in lung","volume":"75","author":"Leng","year":"2015","journal-title":"Cancer Res"},{"key":"2025042605015008200_qzae085-B53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/tx200031q","article-title":"Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools","volume":"24","author":"Pegg","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"2025042605015008200_qzae085-B54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2025042605015008200_qzae085-B55","doi-asserted-by":"crossref","first-page":"e1002539","DOI":"10.1371\/journal.pbio.1002539","article-title":"The deubiquitinase USP47 stabilizes MAPK by counteracting the function of the N-end rule ligase POE\/UBR4 in","volume":"14","author":"Ashton-Beaucage","year":"2016","journal-title":"PLoS Biol"},{"key":"2025042605015008200_qzae085-B56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.febslet.2004.10.071","article-title":"FIGC, a novel FGF-induced ubiquitin-protein ligase in gastric cancers","volume":"578","author":"Jang","year":"2004","journal-title":"FEBS Lett"},{"key":"2025042605015008200_qzae085-B57","first-page":"833","article-title":"Markers of squamocolumnar junction cells in normal tonsils and oropharyngeal cancer with and without HPV infection","volume":"30","author":"Morbini","year":"2015","journal-title":"Histol Histopathol"},{"key":"2025042605015008200_qzae085-B58","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cell.2009.08.037","article-title":"Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling","volume":"139","author":"Hu","year":"2009","journal-title":"Cell"},{"key":"2025042605015008200_qzae085-B59","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/cas.15227","article-title":"High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes","volume":"113","author":"Luo","year":"2022","journal-title":"Cancer Sci"},{"key":"2025042605015008200_qzae085-B60","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1074\/mcp.M111.015529","article-title":"Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays","volume":"11","author":"Hu","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"2025042605015008200_qzae085-B61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-020-00918-x","article-title":"Autoantibody signature in hepatocellular carcinoma using seromics","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2025042605015008200_qzae085-B62","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ijc.34160","article-title":"Combined risk factors and risk of upper gastrointestinal cancer mortality in the linxian general population","volume":"151","author":"Yang","year":"2022","journal-title":"Int J Cancer"},{"key":"2025042605015008200_qzae085-B63","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/sim.1742","article-title":"Presentation of multivariate data for clinical use: the framingham study risk score functions","volume":"23","author":"Sullivan","year":"2004","journal-title":"Stat Med"},{"key":"2025042605015008200_qzae085-B64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","article-title":"The Genome Sequence Archive Family: toward explosive data growth and diverse data types","volume":"19","author":"Chen","year":"2021","journal-title":"Genomics Proteomics Bioinformatics"}],"container-title":["Genomics, Proteomics &amp; Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gpb\/advance-article-pdf\/doi\/10.1093\/gpbjnl\/qzae085\/61051487\/qzae085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gpb\/article-pdf\/22\/6\/qzae085\/61051487\/qzae085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gpb\/article-pdf\/22\/6\/qzae085\/61051487\/qzae085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:02:07Z","timestamp":1745658127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gpb\/article\/doi\/10.1093\/gpbjnl\/qzae085\/7921422"}},"subtitle":[],"editor":[{"given":"Heng","family":"Zhu","sequence":"additional","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/gpbjnl\/qzae085","relation":{},"ISSN":["1672-0229","2210-3244"],"issn-type":[{"value":"1672-0229","type":"print"},{"value":"2210-3244","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,12]]},"article-number":"qzae085"}}